Chinese pharmaceutical firms, including WuXi AppTec and WuXi Biologics, are adjusting their strategies amidst escalating U.S.-China trade tensions. According to a report by Reuters, these companies are stockpiling supplies and considering local testing to mitigate potential disruptions. The trade tensions have prompted concerns over delays in accessing U.S. supply chains and increased import tariffs, causing companies to reconsider project timelines.
Read also: US-China Trade War Update: What Businesses Need to Know
Data from the IndexBox platform highlights the scale of reliance on U.S. imports, with the U.S. exporting diagnostic and laboratory reagents worth approximately $1.4 billion to China in 2024. The pharmaceutical sector in China, which supports global giants like Pfizer and AstraZeneca, is notably affected as companies like WuXi AppTec and Innovent Biologics explore alternatives to U.S.-based reagents to avoid tariff-induced cost increases.
JS Biosciences, a Chinese cell culture media manufacturer, reported that at least 17 biotech and pharmaceutical clients have requested locally-made backup raw materials since April. This move underscores the industry’s concern about potential cost increases and supply chain disruptions. As companies like Innovent Biologics and BeOne Medicines discuss testing U.S. clinical samples domestically, the potential for increased operational costs looms large.
